
Ascendis Pharma wants to bulk up its economic muscles and has therefore started an equity issuance the company hopes can bring in USD 400m (DKK 2.5bn) to the firm.
This comes shortly after the biotech company received approval for its once-weekly growth hormone, Transcon hGH, from the US Food and Drug Administration.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app